p53 tumor suppressor gene therapy for cancer

Cancer Gene Therapy

Volumn 5, Issue 1, 1998, Pages 52-63

  Nielsen, Loretta L ^a   Maneval, Daniel C ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Adenovirus; Gene therapy vectors; Liposomes; p53 gene therapy; p53 tumor suppressor gene; Retrovirus; Review article

Indexed keywords

GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; MULTIMODALITY CANCER THERAPY; NEOPLASM; REVIEW; TUMOR SUPPRESSOR GENE;

COMBINED MODALITY THERAPY; GENE THERAPY; GENES, P53; GENETIC VECTORS; HUMANS; NEOPLASMS;

EID: 0031608678     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Ozbun MA, Butel JS. Tumor suppressor p53 mutations and breast cancer: a critical analysis. Adv Cancer Res. 1995;66:71-141.
2. Selter H, Montenarh M. The emerging picture of p53. Int J Biochem. 1994;26:145-154.
3. Diamandis EP. Clinical applications of the p53 tumor suppressor gene. Clin Chim Acta. 1995;237:79-90.
4. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst. 1996;88:1442-1455.
5. Hainaut P. The tumor suppressor protein p53: a receptor to genotoxic stress that controls cell growth and survival. Curr Opin Oncol. 1995;7:76-82.
6. Chen P-L, Chen Y, Bookstein R, et al. Genetic mechanisms of tumor suppression by the human p53 gene. Science. 1990;250:1576-1580.
7. Roemer K, Friedmann T. Mechanisms of action of the p53 tumor suppressor and prospects for cancer gene therapy by reconstitution of p53 function. Ann N Y Acad Sci. 1994; 716:265-282.
8. Shaw P, Bovey R, Tardy S, et al. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA. 1992;89:4495-4499.
9. Crystal RG. Transfer of genes to humans: early lessons and obstacles to success. Science. 1995;270:404-410.
10. Jolly D. Viral vector systems for gene therapy. Cancer Gene Ther. 1994;1:51-64.
11. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996;272:263-267.
12. Smith RR, Huebner RJ, Rowe WP, et al. Studies on the use of viruses in the treatment of carinoma of the cervix. Cancer. 1956;9:1211-1218.
13. Jain RK. Barriers to drug delivery in solid tumors. Sci Am. 1994:58-65 (July).
14. Zhu N, Liggitt D, Liu Y, et al. Systemic gene expression after intravenous DNA delivery into adult mice. Science. 1993;261:209-211.
15. Nielsen LL, Dell J, Maxwell E, et al. Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Cancer Gene Ther. 1997;4:129-138.
16. Harris MP, Sutjipto S, Wills KN, et al. Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Cancer Gene Ther. 1996;3:121-130.
17. Seth P, Brinkmann U, Schwartz GN, et al. Adenovirus-mediated gene transfer to human breast tumor cells: an approach for cancer gene therapy and bone marrow purging. Cancer Res. 1996;56:1346-1351.
18. Katayose D, Gudas J, Nguyen H, et al. Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells. Clin Cancer Res. 1995;1:889-897.
19. Srivastava S, Katayose D, Tong YA, et al. Recombinant adenovirus vector expressing wild-type p53 is a potent inhibitor of prostate cancer cell proliferation. Urology. 1995;46:843-848.
20. Wroblewski JM, Lay LT, Van Zant G, et al. Selective elimination (purging) of contaminating malignant cells from hematopoietic stem cell autografts using recombinant adenovirus. Cancer Gene Ther. 1996;3:257-264.
21. Wills KN, Maneval DC, Menzel P, et al. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Human Gene Ther. 1994;5:1079-1088.
22. Blagosklonny M, El-Diery WS. In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug. Int J Cancer. 1996;67:386-392.
23. Wang NP, To H, Li W-H, et al. Tumor suppressor activity of Rb and p53 genes in human breast carcinoma cells. Oncogene. 1993;8:279-288.
24. Gallardo D, Drazan KE, McBride WH. Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity. Cancer Res. 1996;56:4891-4893.
25. Mujoo K, Maneval DC, Anderson SC, et al. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene. 1996;12:1617-1623.
26. Santoso JT, Tang D, Lane SB, et al. Adenovirus-based p53 gene therapy in ovarian cancer. Gynec Oncol. 1995;59:171-178.
27. Bacchetti S, Graham FL. Inhibition of cell proliferation by an adenovirus vector expressing the human wild type p53 protein. Int J Oncol. 1993;3:781-788.
28. Hamada K, Alemany R, Zhang W-W, et al. Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer. Cancer Res. 1996;56:3047-3054.
29. Hamada K, Zhang W-W, Alemany R, et al. Growth inhibition of human cervical cancer cells with recombinant adenovirus p53 in vitro. Gynecol Oncol. 1996;60:373-379.
30. Ko SC, Gotoh A, Thalmann GN, et al. Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model. Human Gene Ther. 1996;7:1683-1691.
31. Eastham JA, Hall SJ, Sehgal I, et al. In vivo gene therapy with p35 or p21 adenovirus for prostate cancer. Cancer Res. 1995;55:5151-5155.
32. Yang C, Cirielli C, Capogrossi MC, et al. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res. 1995;55:4210-4213.
33. Gjerset RA, Turla ST, Sobol RE, et al. Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol Carcinog. 1995;14:275-285.
34. Zhang W-W, Fang X, Mazur W, et al. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther. 1994;1:5-13.
35. Zhang W-W, Alemany R, Wang J, et al. Safety evaluation of Ad5CMV-p53 in vitro and in vivo. Human Gene Ther. 1995;6:155-164.
36. Fujiwara T, Grimm EA, Mukhopadhyay T, et al. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. 1994;54:2287-2291.
37. Fujiwara T, Cai DW, Georges RN, et al. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst. 1994;86: 1458-1462.
38. Cai DW, Mukhopadhyay T, Liu Y, et al. Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer. Human Gene Ther. 1993;4:617-624.
39. Fujiwara T, Grimm EA, Mukhopadhyay T, et al. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res. 1993;53:4129-4133.
40. Clayman GL, Liu T-J, Overholt SM, et al. Gene therapy for head and neck cancer: comparing the tumor suppressor gene p53 and a cell cycle regulator WAF1/CIP1 (p21). Arch Otolaryngol Head Neck Surg. 1996;122:489-493.
41. Eicher SA, Clayman GL, Liu T-J, et al. Evaluation of topical gene therapy for head and neck squamous cell carcinoma in an organotypic model. Clin Cancer Res. 1996;2:1659-1664.
42. Clayman GL, El-Naggar AK, Roth JA, et al. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res. 1995;55:1-6.
43. Liu T-J, El-Naggar AK, McDonnell TJ, et al. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res. 1995;55:3117-3122.
44. Li J-H, Li P, Klamut H, et al. Cytotoxic effects of Ad5CMV-p53 expression in two human nasopharyngeal carcinoma cell line. Clin Cancer Res. 1997;3:507-514.
45. Köck H, Harris MP, Anderson SC, et al. Adenovirus-mediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivo. Int J Cancer. 1996;67:808-815.
46. Gomez-Manzano C, Feuyo J, Kyritsis AP, et al. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res. 1996;56:694-699.
47. Badie B, Drazan KE, Kramar MH, et al. Adenovirus-mediated p53 gene delivery inhibits 9L glioma growth in rats. Neurolog Res. 1995;17:209-216.
48. Chen P-L, Chen Y, Arnaiz N, et al. Expression of wild-type p53 in human A673 cells suppresses tumorigenicity but not growth rate. Oncogene. 1991;6:1799-1805.
49. Spitz FR, Nguyen D, Skibber JM, et al. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin Cancer Res. 1996;2:1665-1671.
50. Spitz FR, Nguyen D, Skibber JM, et al. In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer. Anticancer Res. 1996;16:3415-3422.
51. Polyak K, Waldman T, He T-C, et al. Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev. 1996;10:1945-1952.
52. Cirielli C, Riccioni T, Yang C, et al. Adenovirus-mediated gene transfer of wild-type p53 results in melanoma cell apoptosis in vitro and in vivo. Int J Cancer. 1995;63:673-679.
53. Marcellus RC, Teodoro JG, Charbonneau R, et al. Expression of p53 in Saos-2 osteosarcoma cells induces apoptosis which can be inhibited by bcl-2 or the adenovirus E1B-55 kDa protein. Cell Growth Diff. 1996;7:1643-1650.
54. Wang J, Bucana CD, Roth JA, et al. Apoptosis induced in human osteosarcoma cells is one of the mechanisms for the cytocidal effect of Ad5CMV-p53. Cancer Gene Ther. 1995;2:9-17.
55. Ronen D, Schwartz D, Teitz Y, et al. Induction of HL-60 cell to undergo apoptosis is determined by high levels of wild-type p53 protein whereas differentiation of the cells is mediated by lower p53 levels. Cell Growth Diff. 1996;7:21-30.
56. Cheng J, Yee J-K, Yeargin J, et al. Suppression of acute lymphoblastic leukemia by the human wild-type p53 gene. Cancer Res. 1992;52:222-226.
57. Slack RS, Belliveau DJ, Rosenberg M, et al. Adenovirus-mediated gene transfer of the tumor suppressor, p53, induces apoptosis in postmitotic neurons. J Cell Biol. 1996;135:1085-1096.
58. Gurnani M, Dell J, Nielsen LL. Efficacy of SCH58500 in a metastatic model of breast cancer. Proc Am Assoc Cancer Res. 1997;38:13.
59. Xu M, Kumar D, Srinivas S, et al. Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity. Human Gene Ther. 1997;8:177-185.
60. Lesoon-Wood LA, Kim WH, Kleinman HK, et al. Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Human Gene Ther. 1995;6:395-405.
61. Nguyen DM, Spitz FR, Yen N, et al. Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J Thorac Cardiovasc Surg. 1996;112: 1372-1377.
62. Liu T-J, Zhang W-W, Taylor DL, et al. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res. 1994;54:3662-3667.
63. Werthman PE, Drazan KE, Rosenthal JT, et al. Adenoviral-p53 gene transfer to orthotopic and peritoneal murine bladder cancer. J Urol. 1996;155:753-756.
64. Anderson SC, Engler H, Johnson DE, et al. p53 gene therapy in a rat model of hepatocellular carcinoma. Cancer Gene Ther. 1995;2:335-336.
65. Drazan KE, Shen XD, Csete ME, et al. In vivo adenoviral-mediated human p53 tumor suppressor gene transfer and expression in rat liver after resection. Surgery. 1994;116: 197-204.
66. Bao J-J, Zhang W-W, Kuo MT. Adenoviral delivery of recombinant DNA into transgenic mice bearing hepatocellular carcinoma. Human Gene Ther. 1996;7:355-365.
67. Rosenfeld MR, Meneses P, Dalmau J, et al. Gene transfer of wild-type p53 results in restoration of tumor-suppressor function in a medulloblastoma cell line. Neurology. 1995; 45:1533-1539.
68. Vikhanskaya F, Erba E, D'Incalci M, et al. Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53. Nucleic Acids Res. 1994;22: 1012-1017.
69. 3 promote adenovirus internalization but not virus attachment. Cell. 1993;73:309-319.
70. 3 selectively promotes adenovirus-mediated cell membrane permeabilization following internalization. J Cell Biol. 1994;127:257-264.
71. v integrins for infection. J Virol. 1994; 68:6811-6814.
72. v subunit to form a novel vitronectin receptor in a human embryonic kidney cell line. J Biol Chem. 1990;265:5938-5941.
73. Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 1997;275:1320-1323.
74. Paz IB, Cook N, Odom-Maryon T, et al. Human papillomavirus (HPV) in head and neck cancer. Cancer. 1997;79: 595-604.
75. Yang B, Eshleman JR, Berger NA, et al. Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clin Cancer Res. 1996;2:1649-1657.
76. Ehinger M, Bergh G, Olofsson T, et al. Expression of the p53 tumor suppressor gene induces differentiation and promotes induction of differentiation by 1,25-dihydroxycholecalciferol in leukemic U-937 cells. Blood. 1996;87: 1064-1074.
77. Roth JA, Nguyen D, Lawrence DD, et al. Retrovirus-mediated wild-type p53 gene transfer to tumor of patients with lung cancer. Nature Med. 1996;2:985-991.
78. Li Q, Kay MA, Finegold M, et al. Assessment of recombinant adenoviral vectors for hepatic gene therapy. Human Gene Ther. 1993;4:403-409.
79. Drazan KE, Wu L, Shen X, et al. Adenovirus-mediated gene transfer in the transplant setting. Transplantation. 1995;59:670-673.
80. Yang Y, Nunes FA, Berencsi K, et al. Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA. 1994;91:4407-4411.
81. Wilson C, Kay MA. Immunomodulation to enhance gene therapy. Nature Med. 1995;4:887-889.
82. Adesanya MR, Redman RS, Baum BJ, et al. Immediate inflammatory responses to adenovirus-mediated gene transfer in rat salivary glands. Human Gene Ther. 1996;7: 1085-1093.
83. Dameron KM, Volpert OV, Tainsky MA, et al. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science. 1994;265:1582-1584.